Skip to main
EPRX

EPRX Stock Forecast & Price Target

EPRX Analyst Ratings

Based on 2 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Eupraxia Pharmaceuticals Inc. shows significant promise due to the early efficacy data of its product EP-104, which indicates superior "per-patient" outcomes compared to the established treatment dupilumab for eosinophilic esophagitis (EoE). The results from the RESOLVE trial demonstrate not only impressive symptom improvement and sustained therapeutic effects but also a potentially higher efficacy ceiling, with high-dose cohorts achieving a remarkable 94-97% improvement in tissue health scores. Additionally, the removal of a competitor through the CLDX announcement further strengthens Eupraxia's market position and highlights the innovative advantages of its Diffusphere technology.

Bears say

Eupraxia Pharmaceuticals Inc. faces significant risks that contribute to a negative outlook on its stock, primarily due to clinical and regulatory uncertainties surrounding its product, EP-104GI, and the established competition in the market from larger pharmaceutical companies. The company’s reliance on ongoing R&D expenditure increases the potential for financing risk, particularly as the current cash runway may not be sufficient to support extended development phases. Additionally, potential challenges related to cross-border supply and tariffs introduce further instability, exacerbating concerns over the viability and profitability of its product offerings in a competitive landscape.

EPRX has been analyzed by 2 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Eupraxia Pharmaceuticals Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Eupraxia Pharmaceuticals Inc (EPRX) Forecast

Analysts have given EPRX a Buy based on their latest research and market trends.

According to 2 analysts, EPRX has a Buy consensus rating as of Feb 6, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $15.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $15.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Eupraxia Pharmaceuticals Inc (EPRX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.